| LncRNA |
Compound |
Cancer |
P-value |
Effect |
| ENSG00000231028.4 |
ABT-263 (navitoclax) |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
0.020338506 |
Resistant |
| ENSG00000231028.4 |
ABT-263 (navitoclax) |
Liver hepatocellular carcinoma |
0.031440161 |
Sensitive |
